Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leukemia
Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leukemia
Hyper-leukocytosis > 50.109/L is observed in 15% of acute myeloid leukemia (AML).

 Level of hyper-leukocytosis is linearly associated with the incidence of life threatening
 complications that lead to the early death in 25% of these patients.

 The HEAL project is a prospective, uni-centric, observational study that plans to include a
 cohort of 50 patients presenting de novo AML with hyper-leukocytosis (HL) (> 50.109/L) and 10
 controls. The aim of the study is to describe the relative proportion of various hemostasis
 components disturbances, endothelium alterations, platelet dysfunction and to calculate
 cumulative incidence of hemorrhagic and thrombotic complications as well as overall survival
 of patients presenting with HL AML.
Inclusion Criteria:

 -  De novo AML

 -  GB counts > 50 G/L

 -  Eligible for intensive chemotherapy

 -  no previous AML treatment

 Exclusion Criteria:

 -  secondary AML

 -  relapse of AML

 -  Acute promyelocytic leukemia

 -  Previous antiplatelet or anticoagulant treatment